These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 29462880

  • 1. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
    Singh K, Munuganti RSN, Lallous N, Dalal K, Yoon JS, Sharma A, Yamazaki T, Cherkasov A, Rennie PS.
    Int J Mol Sci; 2018 Feb 15; 19(2):. PubMed ID: 29462880
    [Abstract] [Full Text] [Related]

  • 2. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
    Singh K, Munuganti RS, Leblanc E, Lin YL, Leung E, Lallous N, Butler M, Cherkasov A, Rennie PS.
    Breast Cancer Res; 2015 Feb 25; 17(1):27. PubMed ID: 25848700
    [Abstract] [Full Text] [Related]

  • 3. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, Weir HM, Puhalla SL, Davidson NE, Stern AM, Chu D, Park BH, Lee AV, Oesterreich S.
    Breast Cancer Res; 2017 May 23; 19(1):60. PubMed ID: 28535794
    [Abstract] [Full Text] [Related]

  • 4. Loss of Estrogen-Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer.
    Zhang W, Wu M, Chong QY, Zhang M, Zhang X, Hu L, Zhong Y, Qian P, Kong X, Tan S, Li G, Ding K, Lobie PE, Zhu T.
    Cancer Res; 2018 Sep 01; 78(17):4915-4928. PubMed ID: 29945962
    [Abstract] [Full Text] [Related]

  • 5. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
    Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, Sinn HP, Schneeweiss A, Deuschle U, Zapatka M, Heck S, Lichter P.
    Cancer Res; 2015 Feb 15; 75(4):720-31. PubMed ID: 25643697
    [Abstract] [Full Text] [Related]

  • 6. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.
    Mol Cancer Res; 2008 Aug 15; 6(8):1347-55. PubMed ID: 18708366
    [Abstract] [Full Text] [Related]

  • 7. STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation.
    Hou Y, Li X, Li Q, Xu J, Yang H, Xue M, Niu G, Zhuo S, Mu K, Wu G, Li X, Wang H, Zhu J, Zhuang T.
    J Cell Mol Med; 2018 Dec 15; 22(12):6077-6086. PubMed ID: 30334368
    [Abstract] [Full Text] [Related]

  • 8. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O, Seghers S, Sergoynne L, Van Gaver H, Papadimitriou K, Wouters K, Trinh XB, Huizing MT, Tjalma W.
    Biochim Biophys Acta Rev Cancer; 2019 Dec 15; 1872(2):188315. PubMed ID: 31647985
    [Abstract] [Full Text] [Related]

  • 9. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS, Li Y, Zhang H, Zhang D, Zhang XB, Wang X, Yu Y.
    Theranostics; 2020 Dec 15; 10(23):10729-10742. PubMed ID: 32929377
    [Abstract] [Full Text] [Related]

  • 10. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, Liu Q, Hu P, Murphy LC, Raouf A.
    Cell Physiol Biochem; 2018 Dec 15; 51(4):1518-1532. PubMed ID: 30497079
    [Abstract] [Full Text] [Related]

  • 11. Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
    Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W.
    Oncotarget; 2016 Jun 07; 7(23):33901-18. PubMed ID: 27129152
    [Abstract] [Full Text] [Related]

  • 12. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS, Lee MH, Lee MO.
    Breast Cancer Res Treat; 2020 Feb 07; 180(1):45-54. PubMed ID: 31897900
    [Abstract] [Full Text] [Related]

  • 13. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
    Busonero C, Leone S, Bianchi F, Acconcia F.
    Cell Oncol (Dordr); 2018 Dec 07; 41(6):677-686. PubMed ID: 30182339
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.
    Clin Cancer Res; 2015 Nov 15; 21(22):5121-5130. PubMed ID: 25991817
    [Abstract] [Full Text] [Related]

  • 15. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL, Hancock M, Sun S, Gersch CL, Larios JM, David W, Hu J, Hayes DF, Wang S, Rae JM.
    Breast Cancer Res Treat; 2020 Apr 15; 180(3):611-622. PubMed ID: 32067153
    [Abstract] [Full Text] [Related]

  • 16. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.
    Nathan S, Ma Y, Tomita YA, De Oliveira E, Brown ML, Rosen EM.
    Breast Cancer Res Treat; 2017 Dec 15; 166(3):681-693. PubMed ID: 28808806
    [Abstract] [Full Text] [Related]

  • 17. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
    Yu-Rice Y, Jin Y, Han B, Qu Y, Johnson J, Watanabe T, Cheng L, Deng N, Tanaka H, Gao B, Liu Z, Sun Z, Bose S, Giuliano AE, Cui X.
    Oncogene; 2016 Oct 13; 35(41):5400-5411. PubMed ID: 27041579
    [Abstract] [Full Text] [Related]

  • 18. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.
    Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, Houtman R, Irwin S, Joshi JJ, Karr C, Kim A, Kumar N, Kumar P, Kuznetsov G, Lai WG, Larsen N, Mackenzie C, Martin LA, Melchers D, Moriarty A, Nguyen TV, Norris J, O'Shea M, Pancholi S, Prajapati S, Rajagopalan S, Reynolds DJ, Rimkunas V, Rioux N, Ribas R, Siu A, Sivakumar S, Subramanian V, Thomas M, Vaillancourt FH, Wang J, Wardell S, Wick MJ, Yao S, Yu L, Warmuth M, Smith PG, Zhu P, Korpal M.
    Cancer Discov; 2018 Sep 13; 8(9):1176-1193. PubMed ID: 29991605
    [Abstract] [Full Text] [Related]

  • 19. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.
    Endocr Relat Cancer; 2006 Dec 13; 13(4):1121-33. PubMed ID: 17158758
    [Abstract] [Full Text] [Related]

  • 20. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
    Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL.
    Elife; 2018 Nov 29; 7():. PubMed ID: 30489256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.